Objective-To test the hypothesis that short term application of transdermal scopolamine increases heart rate variability (HRV) and restores sympathovagal balance in patients with stable congestive heart failure (CHF). Design-A double blind placebo controlled crossover study. Setting-Tertiary referral centre. Patients-Twelve patients (mean age 66 (10)) with New York Heart Association class II-IV CHF. All patients had coronary artery disease (mean left ventricular ejection fraction 26-7 (8'9) %). Intervention-Patients were randomly assigned to receive either a placebo skin patch or a transdermal scopolamine patch (Transderm, 0 05 mg/h). Patches remained in place for 48 hours with a 24 hour washout period before crossover. Outcome measures-HRV was derived from (a) 24 hour time domain indices (mean RR interval, standard deviation of interbeat interval, and the baseline width of the frequency distribution of RR intervals) and (b) short data set (2.2 mm) power spectral measurements using autoregressive modelling. Autospectral measures were performed in both resting supine and standing (orthostatic) states. The 24 hour Holter record was obtained during the second day of patch application. Results-There was a small but significant (P < 0 05) increase in all time domain HRV variables with scopolamine. There was a paradoxical fall in low frequency (LF) spectral power induced by orthostasis during baseline (-30%) and placebo (-34%) states. Conversely, scopolamine was associated with a 14% increase in LF power during orthostatic stress. Scopolamine thus significantly reduced the orthostatic fall in LF (P < 0*01) compared with either baseline or placebo values. No difference in circadian rhythm was seen between the scopolamine and placebo treatment periods. However, the abrupt fall in the high frequency (vagal) power during the early morning sleep-wake hours was reduced by scopolamine. Scopolamine was also associated with a significant rightward shift in the resting LF central frequency consistent with a vagomimetic effect.
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Results-There was a small but significant (P < 0 05) increase in all time domain HRV variables with scopolamine. There was a paradoxical fall in low frequency (LF) spectral power induced by orthostasis during baseline (-30%) and placebo (-34%) states. Conversely, scopolamine was associated with a 14% increase in LF power during orthostatic stress. Scopolamine thus significantly reduced the orthostatic fall in LF (P < 0*01) compared with either baseline or placebo values. No difference in circadian rhythm was seen between the scopolamine and placebo treatment periods. However, the abrupt fall in the high frequency (vagal) power during the early morning sleep-wake hours was reduced by scopolamine. Scopolamine was also associated with a significant rightward shift in the resting LF central frequency consistent with a vagomimetic effect.
Conclusion-Patients with chronic stable
CHF showed a paradoxical fall in the low frequency (sympathetic) power during orthostatic stress. Transdermal scopolamine applied over a 48 hour period partially restored the balance between sympathetic tone and vagal activity in CHF patients and maintained this balance during orthostatic stress.
(Heart 1996;76:137-143) Keywords: power spectrum; time domain analysis; scopolamine; left ventricular dysfunction Though chronic congestive heart failure (CHF) begins as a cardiac disorder there is often progression to systemic manifestations such as overcompensated neurohumoral activation,' depression of arterial baroreceptor sensitivity,2 and depressed vagal modulation of sinoatrial activity.3 Accordingly there is persuasive (albeit circumstantial) evidence that heightened sympathetic tone coupled with depressed cardiac vagal activity predisposes cardiac patients to unstable ventricular tachyarrhythmias and sudden cardiac death. 45 Reduced heart rate variability (HRV), expressed in either time or frequency domains, is a common finding in patients with depressed left ventricular function.36 Since reduced HRV is independently predictive of cardiac death after recovery from acute myocardial infarction,57 it is postulated that patients with CHF, regardless of aetiology, may be at an equally high risk 
Patients and methods
We studied 12 patients, 10 men and two women. All patients had coronary artery disease documented by a history of previous myocardial infarction, a positive exercise test, or coronary angiography. All complained of effort dyspnoea and/or effort intolerance. Four of the patients were in NYHA class II; seven in class III, and one in class IV. Their mean age was 66 (10) years and their average resting LV ejection fraction, by radionuclide angiocardiography, was 26-7 (8-9) %. All patients were in sinus rhythm at the time of study. Patients were free of glaucoma, urinary tract obstruction, and symptomatic bradycardia. Patients continued with their usual antifailure medications throughout the study with no change in dosage. These included digoxin (77%); ACE inhibitor (77%), and diuretics (69% For the time domain analysis the 24 hour Holter tape was first annotated using an Oxford Medilog Excel scanner. A beat to beat recognition software algorithm assigned a configuration class to each QRS complex. With operator assistance, differentiation and separation of normal interbeat sequences (N-N) from premature ventricular ectopic beats were performed. The normal sinus conducted (N-N) beats were then reassigned and a second software program downloaded all N-N interbeat intervals to a floppy disk for further analysis. Three time domain variables were then computed. These included the mean N-N interval over 24 hours, the standard deviation of these N-N intervals (SDNN), and the base width of the frequency histogram of sequential N-N intervals as described by Malik et al. '9 The power spectrum of HRV was computed using autoregressive modelling. 20 The ECG signals were passed through analogue filters with their 3 dB cut-off frequencies set to 1 to 100 Hz. The filtered ECG signal was digitised using a 12 bit analogue to digital converter at a rate of 1 kHz. A beat to beat heart rate series was computed from the interval tachogram. This instantaneous heart rate series was resampled using linear interpolation to obtain an equally sampled time domain signal spaced 0-5 s apart. The power spectrum was then computed from the HRV data of 256 samples (128 s). An autoregressive model order number of 14 was fitted to the HRV signal.
Both the peak power (bt/min2/Hz) and normalised area power (nu) contained in the low frequency (0-05-0-15 Hz) and high frequency (0-15-0-40 Hz) spectral bands were derived.'021 In addition to being used to estimate the maximum power at specific frequencies, the peak power was also used to identify shifts in the central frequency of the low frequency band while the normalised area measurement was computed as the fractional energy contained within the integrated area subtended by each spectral band.
The autoregressive technique is applicable to short data sets but requires steady state conditions which cannot always be assured during ambulatory monitoring. Moreover, because of the reduced short term variance and autospectral energies in patients with CHF (especially under supine conditions) the low signal to noise ratio makes it difficult to be certain of any reliable effect of a given intervention. Hence, in addition to computing the power spectrum averaged over each hour throughout the 24 hour cycle, we chose to examine the orthostatic response of the heart rate autospectrum under controlled conditions thus assuring a more reliable and more reproducible deterministic low frequency signal.2' DATA ANALYSIS Reproducibility and stationarity of the time Figure 2 Percentage change in the low frequency (LF) peak power from supine to standing position during baseline, scopolamine, and placebo states. Placebo 1 and placebo 2 refer to the pre and post scopolamine phases respectively (n = 6 each). *P < 0 05 compared with either baseline or placebo conditions. Note the reproducibility of the orthostatic response of the LF peak power between baseline and placebo states.
to 814 ms compared with either placebo (741 ms) or baseline (741 ms). The fig 2) . Moreover, the consistency in the degree of the orthostatic drop in LF power was seen whether or not the placebo phase preceded or followed scopolamine.
As an illustration of scopolamine's effect on frequency domain variables, the heart rate power spectra from one of the patients is shown in fig 3. Sequential spectra (each 2-2 mm duration) are displayed in a stacked series over 15-20 min. These plots reveal an orthostatic fall in LF power while the patient was on the placebo patch (bottom panels). With scopolamine there is reduction in the decrease in LF power on standing. There was depressed vagal modulation (HF band) regardless whether the patient was on placebo or scopolamine. Little evidence of deterministic oscillations in the vagal band was observed while the patients were taking scopolamine. There was also a rightward shift in the LF central frequency on standing, a phenomenon characteristic of the vagomimetic effects of low dose atropine.12 CIRCADIAN 
RHYTHM
Although scopolamine enhanced the overall variability of 24 h time domain indices, the autospectral pattern of circadian variation was unaffected by scopolamine (table 3) . Nonetheless, for each six hours of recording the average RR interval was greater and the LF:HF ratio smaller with scopolamine than with placebo (table 3) . Moreover, scopolamine reduced the rapid fall in the HF (vagal) power during the early morning hours. This was demonstrated by the sequential percentage changes in the HF peak power during the hours of 6-10 am (fig 4) . No significant changes were seen at night. At 5 am the absolute HF peak power was 32-5 (bt/ min)2/Hz for placebo (squares) and 31 8 (bt/ min)2/Hz for scopolamine (triangles). The graph illustrates the subsequent percentage change in the HF power during the transition reasons for using an orthostatic test in these CHF patients. First, it is well established that the HR variance or the sum of energies contained in the frequency spectrum of heart failure patients is significantly reduced.3 This makes it difficult to dissociate, quantitatively, the deterministic cycles of physiological rhythms in the power spectrum from background noise, especially for short term data sets. For instance, in our patients the signal to noise ratio of the HF power band for any 2-2 min segment was extremely low (average HF peak power < 16 bt/min2/Hz) making it difficult reliably to quantify changes in the spectral energies within the HF (vagal) band. This presents a special problem because previous studies showed that low dose scopolamine increases vagal tone in both healthy controls and those with coronary disease.1415 On the other hand, the LF power in our subjects (average 67 bt/min2/Hz) was well above noise level. Second, by using orthostatic stress to perturb integrated autonomic pathways, we were able to show a reproducible yet paradoxical orthostatic fall of 30-34% in the LF power. This abnormal decrease was prevented by scopolamine, suggesting partial restitution of autonomic control of sinus node function in patients with CHF. Although the rightward shift in the LF central frequency was small, albeit statistically significant, it nevertheless adds support to a cardiac vagomimetic effect of scopolamine'2 despite a negligible effect on HF power during short term controlled readings. When the signal was computed over a longer data set (for example, 24 h) the variance was more robust but we were still unable to discern a significant change in the absolute or normalised HF power. The decrease in the average hourly LF:HF power with scopolamine indicated a reduction in sympathetic modulation during ambulatory activity.
AUTONOMIC EFFECTS OF SCOPOLAMINE
It is well established that low dose anticholinergic drugs can cause bradycardia. 14 24 The results of our study may be a small step towards resolving some of these important clinical issues.
In conclusion, three observations are worthy of note. First, a paradoxical fall in the LF power during orthostatic stress confirmed impaired sympatho-vagal balance in these CHF patients. Second, transdermal scopolamine applied over a 48 hour period partially restored autonomic balance in patients with chronic stable heart failure by increasing HRV and reducing the orthostatic fall in LF power. Third, orthostatic stress may prove to be a useful manoeuvre in testing autonomic function in patients with CHF or autonomic neuropathy where the power spectrum contains low energy signals at rest.
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